Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption

James E. Haddow, Monica R. McClain, Glenn E. Palomaki, Louis M. Neveux, Geralyn Lambert-Messerlian, Jacob A. Canick, Fergal D. Malone, T. Flint Porter, David A. Nyberg, Peter S. Bernstein, Mary E. D'Alton

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To estimate the relationship between thyroid antibodies and placental abruption. Methods: This cohort study assesses thyroperoxidase and thyroglobulin antibodies in relation to placental abruption among 10,062 women with singleton viable pregnancies (from the First and Second Trimester Risk of Aneuploidy [FaSTER] trial). A thyroperoxidase antibody cutoff of 50 international units/mL is used for comparison with published data from another cohort. Results: Women with elevated thyroperoxidase antibody levels in the first and second trimesters have a higher rate of placental abruption than antibody-negative women. This relationship is less strong in the first trimester (1.51% compared with 0.83%; odds ratio [OR], 1.83; 95% confidence interval [CI], 0.99-3.37) than in the second trimester (1.78% compared with 0.82%; OR, 2.20; 95% CI, 1.21-3.99). A similar, but weaker, relationship is present for thyroglobulin antibodies. Sixty-four of 782 thyroperoxidase antibody-positive pregnancies without abruption become negative by the second trimester; one pregnancy with abruption becomes antibody-positive. Odds ratios for pregnancies with both thyroperoxidase and thyroglobulin antibody elevations are also higher (first trimester: OR, 2.10; 95% CI, 0.91-4.86; second trimester: OR, 2.73; 95% CI, 1.17-6.33). Conclusion: The present data confirm an association between thyroid antibody elevations and placental abruption described in a recent report. These findings, however, do not provide support for recommending routine testing for thyroid antibodies during pregnancy.

Original languageEnglish (US)
Pages (from-to)287-292
Number of pages6
JournalObstetrics and Gynecology
Volume117
Issue number2 PART 1
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Abruptio Placentae
Thyroglobulin
Pregnancy
Antibodies
Second Pregnancy Trimester
First Pregnancy Trimester
Odds Ratio
Confidence Intervals
Thyroid Gland
Aneuploidy
Cohort Studies

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Haddow, J. E., McClain, M. R., Palomaki, G. E., Neveux, L. M., Lambert-Messerlian, G., Canick, J. A., ... D'Alton, M. E. (2011). Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. Obstetrics and Gynecology, 117(2 PART 1), 287-292. https://doi.org/10.1097/AOG.0b013e31820513d9

Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. / Haddow, James E.; McClain, Monica R.; Palomaki, Glenn E.; Neveux, Louis M.; Lambert-Messerlian, Geralyn; Canick, Jacob A.; Malone, Fergal D.; Porter, T. Flint; Nyberg, David A.; Bernstein, Peter S.; D'Alton, Mary E.

In: Obstetrics and Gynecology, Vol. 117, No. 2 PART 1, 02.2011, p. 287-292.

Research output: Contribution to journalArticle

Haddow, JE, McClain, MR, Palomaki, GE, Neveux, LM, Lambert-Messerlian, G, Canick, JA, Malone, FD, Porter, TF, Nyberg, DA, Bernstein, PS & D'Alton, ME 2011, 'Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption', Obstetrics and Gynecology, vol. 117, no. 2 PART 1, pp. 287-292. https://doi.org/10.1097/AOG.0b013e31820513d9
Haddow JE, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA et al. Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. Obstetrics and Gynecology. 2011 Feb;117(2 PART 1):287-292. https://doi.org/10.1097/AOG.0b013e31820513d9
Haddow, James E. ; McClain, Monica R. ; Palomaki, Glenn E. ; Neveux, Louis M. ; Lambert-Messerlian, Geralyn ; Canick, Jacob A. ; Malone, Fergal D. ; Porter, T. Flint ; Nyberg, David A. ; Bernstein, Peter S. ; D'Alton, Mary E. / Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. In: Obstetrics and Gynecology. 2011 ; Vol. 117, No. 2 PART 1. pp. 287-292.
@article{a195842fbdf74d5aafb7b7b985f0944f,
title = "Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption",
abstract = "Objective: To estimate the relationship between thyroid antibodies and placental abruption. Methods: This cohort study assesses thyroperoxidase and thyroglobulin antibodies in relation to placental abruption among 10,062 women with singleton viable pregnancies (from the First and Second Trimester Risk of Aneuploidy [FaSTER] trial). A thyroperoxidase antibody cutoff of 50 international units/mL is used for comparison with published data from another cohort. Results: Women with elevated thyroperoxidase antibody levels in the first and second trimesters have a higher rate of placental abruption than antibody-negative women. This relationship is less strong in the first trimester (1.51{\%} compared with 0.83{\%}; odds ratio [OR], 1.83; 95{\%} confidence interval [CI], 0.99-3.37) than in the second trimester (1.78{\%} compared with 0.82{\%}; OR, 2.20; 95{\%} CI, 1.21-3.99). A similar, but weaker, relationship is present for thyroglobulin antibodies. Sixty-four of 782 thyroperoxidase antibody-positive pregnancies without abruption become negative by the second trimester; one pregnancy with abruption becomes antibody-positive. Odds ratios for pregnancies with both thyroperoxidase and thyroglobulin antibody elevations are also higher (first trimester: OR, 2.10; 95{\%} CI, 0.91-4.86; second trimester: OR, 2.73; 95{\%} CI, 1.17-6.33). Conclusion: The present data confirm an association between thyroid antibody elevations and placental abruption described in a recent report. These findings, however, do not provide support for recommending routine testing for thyroid antibodies during pregnancy.",
author = "Haddow, {James E.} and McClain, {Monica R.} and Palomaki, {Glenn E.} and Neveux, {Louis M.} and Geralyn Lambert-Messerlian and Canick, {Jacob A.} and Malone, {Fergal D.} and Porter, {T. Flint} and Nyberg, {David A.} and Bernstein, {Peter S.} and D'Alton, {Mary E.}",
year = "2011",
month = "2",
doi = "10.1097/AOG.0b013e31820513d9",
language = "English (US)",
volume = "117",
pages = "287--292",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2 PART 1",

}

TY - JOUR

T1 - Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption

AU - Haddow, James E.

AU - McClain, Monica R.

AU - Palomaki, Glenn E.

AU - Neveux, Louis M.

AU - Lambert-Messerlian, Geralyn

AU - Canick, Jacob A.

AU - Malone, Fergal D.

AU - Porter, T. Flint

AU - Nyberg, David A.

AU - Bernstein, Peter S.

AU - D'Alton, Mary E.

PY - 2011/2

Y1 - 2011/2

N2 - Objective: To estimate the relationship between thyroid antibodies and placental abruption. Methods: This cohort study assesses thyroperoxidase and thyroglobulin antibodies in relation to placental abruption among 10,062 women with singleton viable pregnancies (from the First and Second Trimester Risk of Aneuploidy [FaSTER] trial). A thyroperoxidase antibody cutoff of 50 international units/mL is used for comparison with published data from another cohort. Results: Women with elevated thyroperoxidase antibody levels in the first and second trimesters have a higher rate of placental abruption than antibody-negative women. This relationship is less strong in the first trimester (1.51% compared with 0.83%; odds ratio [OR], 1.83; 95% confidence interval [CI], 0.99-3.37) than in the second trimester (1.78% compared with 0.82%; OR, 2.20; 95% CI, 1.21-3.99). A similar, but weaker, relationship is present for thyroglobulin antibodies. Sixty-four of 782 thyroperoxidase antibody-positive pregnancies without abruption become negative by the second trimester; one pregnancy with abruption becomes antibody-positive. Odds ratios for pregnancies with both thyroperoxidase and thyroglobulin antibody elevations are also higher (first trimester: OR, 2.10; 95% CI, 0.91-4.86; second trimester: OR, 2.73; 95% CI, 1.17-6.33). Conclusion: The present data confirm an association between thyroid antibody elevations and placental abruption described in a recent report. These findings, however, do not provide support for recommending routine testing for thyroid antibodies during pregnancy.

AB - Objective: To estimate the relationship between thyroid antibodies and placental abruption. Methods: This cohort study assesses thyroperoxidase and thyroglobulin antibodies in relation to placental abruption among 10,062 women with singleton viable pregnancies (from the First and Second Trimester Risk of Aneuploidy [FaSTER] trial). A thyroperoxidase antibody cutoff of 50 international units/mL is used for comparison with published data from another cohort. Results: Women with elevated thyroperoxidase antibody levels in the first and second trimesters have a higher rate of placental abruption than antibody-negative women. This relationship is less strong in the first trimester (1.51% compared with 0.83%; odds ratio [OR], 1.83; 95% confidence interval [CI], 0.99-3.37) than in the second trimester (1.78% compared with 0.82%; OR, 2.20; 95% CI, 1.21-3.99). A similar, but weaker, relationship is present for thyroglobulin antibodies. Sixty-four of 782 thyroperoxidase antibody-positive pregnancies without abruption become negative by the second trimester; one pregnancy with abruption becomes antibody-positive. Odds ratios for pregnancies with both thyroperoxidase and thyroglobulin antibody elevations are also higher (first trimester: OR, 2.10; 95% CI, 0.91-4.86; second trimester: OR, 2.73; 95% CI, 1.17-6.33). Conclusion: The present data confirm an association between thyroid antibody elevations and placental abruption described in a recent report. These findings, however, do not provide support for recommending routine testing for thyroid antibodies during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=79251572044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251572044&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31820513d9

DO - 10.1097/AOG.0b013e31820513d9

M3 - Article

C2 - 21252741

AN - SCOPUS:79251572044

VL - 117

SP - 287

EP - 292

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2 PART 1

ER -